Pfizer's (PFE) Talzenna plus Xtandi significantly improves radiographic progression-free survival in metastatic prostate cancer; meets primary endpoint with significant improvement in RPFS
Context
Pfizer's successful trial of Talzenna plus Xtandi in metastatic prostate cancer highlights potential for significant revenue growth through advanced oncology treatments. This positive data may boost investor confidence in PFE's pipeline and could lead to an upward revision in future earnings estimates as the product approaches market introduction.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#PFIZER INC#PFE.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES